SI-BONE (SIBN) opened Q1 2026 with revenue of US$52.6 million and a basic EPS loss of US$0.10, while the trailing 12 month figures show revenue of US$206.2 million and a basic EPS loss of US$0.39. This keeps the focus squarely on how quickly margins might tighten or widen from here. The company has seen quarterly revenue move from US$47.3 million in Q1 2025 to US$52.6 million in Q1 2026, with basic EPS losses over that span ranging between roughly US$0.04 and US$0.15. The latest print lands in the middle of its recent range and places the spotlight firmly on the pace of loss reduction and the path toward cleaner margins.

See our full analysis for SI-BONE.

With the latest numbers on the table, the next step is to set these results against the widely followed narratives around growth, profitability, and risk to see which views hold up and which need a rethink.

TTM losses narrow to US$16.7 million

• On a trailing 12 month basis, SI-BONE reported US$206.2 million in revenue and a net loss of US$16.7 million, compared with a TTM loss of US$30.9 million six quarters ago as revenue moved from US$167.2 million to US$206.2 million.
• What stands out for the bullish narrative is that this five year trend of losses shrinking by about 15% per year sits alongside revenue forecasts of roughly 13.2% annual growth. Yet
  • forecasts cited in that optimistic view still do not point to profitability in the next three years, even though trailing losses have already narrowed from US$30.9 million to US$16.7 million,
  • and current TTM revenue of US$206.2 million is below the US$291.2 million to US$314.5 million levels that bullish and bearish scenarios reference for several years out, so today’s improvement is only one piece of a much larger earnings gap.

Some investors who buy into the bullish story focus on how this narrowing loss profile might set up the next phase of the business, while others question whether the earnings bridge to those future scenarios is steep enough to justify aggressive assumptions about margins and scale. 🐂 SI-BONE Bull Case

Quarterly revenue step up, profitability still work in progress

• Quarterly revenue moved from US$47.3 million in Q1 2025 to US$52.6 million in Q1 2026, while the quarterly net loss narrowed from US$6.5 million to US$4.3 million over the same period, with basic EPS loss moving from about US$0.15 to about US$0.10.
• Bears point out that, despite this progress, the company is still unprofitable and is not forecast to reach profitability within the next three years, which lines up with
  • the most recent four quarters still adding up to a TTM loss of US$16.7 million and basic EPS loss of about US$0.39,
  • and ongoing comments that continued investment in R&D and sales infrastructure is needed to support product launches and international growth, which can keep expenses high relative to revenue even as quarterly losses shrink.

For cautious investors, the key question is whether this pattern of smaller quarterly losses can continue long enough to close the gap that bearish analysts tie to their long range earnings and margin assumptions. 🐻 SI-BONE Bear Case

Valuation sits below peers at 2.6x P/S

• The stock is trading on a P/S of about 2.6x compared with peer and US Medical Equipment industry averages of about 3.0x and 2.8x, while the current share price of US$13.90 sits below both the allowed analyst target of US$24.13 and a cited DCF fair value of US$47.57.
• Analysts’ consensus view links this discount to a mix of faster forecast revenue growth and continued losses, so
  • the roughly 13.2% revenue growth forecast and five year track record of losses shrinking by about 15% per year help explain why some see room for the valuation to close part of the gap to the US$24.13 target,
  • while the expectation that the business remains loss making over at least the next three years sets a ceiling on how quickly some investors may expect that P/S discount versus peers at 3.0x and the industry at 2.8x to change.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for SI-BONE on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed on the outlook after all of that? Use the figures, valuations, and narratives above to evaluate the story for yourself, then weigh the 4 key rewards and 2 important warning signs

See What Else Is Out There

SI-BONE still reports ongoing losses, is not forecast to be profitable within the next three years, and trades at a discount while carrying execution risk on margins.

If that mix of continued losses and uncertainty makes you cautious, you might consider balancing your portfolio by checking companies in the 69 resilient stocks with low risk scores that aim for steadier performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.